Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Quick Stats
Jun 24, 202655.9
AI Score
HOLD4.61
Volume Ratio
Aug 13, 2026
Next Earnings
17
+ve Days (30d)
13
-ve Days (30d)
GALT Stock Summary
Last updated Jun 24, 2026
GALT is currently trading at $3.92, positioned above its 200-day moving average of $3.73, indicating a long-term uptrend. The stock has a 52-week range of $2.025 to $7.13.
Technical Analysis: The 50-day moving average stands at $2.45, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 81.842, suggesting the stock is in overbought territory (bullish but caution advised).
Money Flow Indicators: The Chaikin Money Flow (20-day) is -0.026, which is negative, suggesting distribution or selling pressure. Our AI-powered investment score rates GALT at 55.9/100 with a HOLD recommendation.
GALT (Galectin Therapeutics Inc.) Indicators
Last updated Jun 24, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 81.842 |
| CMF (20) | -0.026 |
| ROC (10) | 61.407 |
| ADX (14) | 31.045 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.212 |
| AROONOSC (14) | 85.714 |
| WILLAMS %R (14) | -4.111 |
| MFI (14) | 89.313 |
GALT Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Select indicators above to analyze technical patterns
Indicators will appear below the price chart with perfectly aligned datesVolume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
GALT Price vs Max Options Open Interest
GALT Max Change In Options Open Interest
GALT Options - Sort by Max open Interest (near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GALT Daily Out of Money Options - Sort by Max open Interest (near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GALT Daily In the Money Options - Sort by Max open Interest (near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
GALT Most Active Options by Volume(near term)
24th June 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
Galectin Therapeutics Inc. is not trading above both 50 Day and 200 Day SMA which is considered Bearish.
GALT Moving Averages Analysis
Galectin Therapeutics Inc. has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Jun 24, 2026
Galectin Therapeutics Inc. has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Jun 24, 2026
GALT (Galectin Therapeutics Inc.) Simple Moving Averages
Moving Averages are last updated Jun 24, 2026
| Days | MA |
|---|---|
| 10 | 2.84 |
| 20 | 2.65 |
| 30 | 2.54 |
| 50 | 2.45 |
| 100 | 2.65 |
| 200 | 3.73 |
GALT Fundamental Analysis
| P/E (Forward) | 4.5434 |
| P/E (Trailing) | -- |
| Market Cap ($) | 184.4 million |
| Earnings/Share ($) | -0.41 |
| Net Proft Margin (%) | 0 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.37 |
| EPS Estimate Next Year ($) | -0.33 |
| WallStreet Target Price ($) | 11 |
| Most Recent Quarter |
Galectin Therapeutics (GALT) has been the subject of active discussion on Stocktwits, with some users referring to it as a 'TURD TICKER.' The company's recent developments, including presentations at the MASH-TAG conference, have garnered attention from key opinion leaders advising the FDA on liver disease drug development policy. Galectin Therapeutics' belapectin drug is receiving favorable attention, with potential partnerships and price point increases being speculated. Key figures in the industry, such as Mary Rinella and Naga Chalasani, are showing support for Galectin Therapeutics' research and development efforts.
Updated 2026-01-11 17:00:02